Literature DB >> 17318603

Detection of brain metastasis at 3T: comparison among SE, IR-FSE and 3D-GRE sequences.

Shingo Kakeda1, Yukunori Korogi, Yasuhiro Hiai, Norihiro Ohnari, Junji Moriya, Koji Kamada, Mai Hanamiya, Toru Sato, Mika Kitajima.   

Abstract

The objective of this study is to compare the detectability of brain metastases at 3T among three contrast-enhanced sequences, spin-echo (SE) sequence, inversion recovery fast SE (IR-FSE) sequence (both with section thickness of 6 mm), and three-dimensional fast spoiled gradient-echo (3D fast SPGR) sequence with 1.4 mm isotropic voxel. First, phantom studies were performed to quantify the contrast-enhancement ratio (CER) with three sequences. In 21 consecutive patients with brain metastases, axial images of three sequences at 3T were obtained after administration of gadoteridol. Two neuroradiologists assessed the detectability of brain metastases for the three sequences. In the phantom study, no evident difference in the CER was demonstrated among three sequences. Significantly more brain metastases were detected with 3D fast SPGR than with SE and IR-FSE (a total of 97 lesions with 3D fast SPGR vs. 64 with SE and 63 with IR-FSE). In particular, 3D fast SPGR was superior to the other two sequences in detection of the small lesions (<3 mm). At 3T, the contrast-enhanced 3D fast SPGR with 1.4 mm isotropic voxel is clinically more valuable for detecting small brain metastases than the SE and IR-FSE with section thickness of 6 mm.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318603     DOI: 10.1007/s00330-007-0599-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  20 in total

1.  MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence--initial experience in the brain.

Authors:  M Brant-Zawadzki; G D Gillan; W R Nitz
Journal:  Radiology       Date:  1992-03       Impact factor: 11.105

2.  The high-field-strength curmudgeon.

Authors:  Jeffrey S Ross
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

Review 3.  The optimal use of contrast agents at high field MRI.

Authors:  Siegfried Trattnig; Kathia Pinker; Ahmed Ba-Ssalamah; Iris-Melanie Nöbauer-Huhmann
Journal:  Eur Radiol       Date:  2006-03-01       Impact factor: 5.315

4.  Eye imaging with a 3.0-T MRI using a surface coil--a study on volunteers and initial patients with uveal melanoma.

Authors:  Arne-Jörn Lemke; Minouche Alai-Omid; Susanne Anja Hengst; Iris Kazi; Roland Felix
Journal:  Eur Radiol       Date:  2006-01-06       Impact factor: 5.315

5.  Can tumor contrast enhancement be used as a criterion for differentiating tumor grades of oligodendrogliomas?

Authors:  Matthew L White; Yan Zhang; Patricia Kirby; Timothy C Ryken
Journal:  AJNR Am J Neuroradiol       Date:  2005-04       Impact factor: 3.825

6.  Value of diffusion-weighted imaging and apparent diffusion coefficient in recent cerebral infarctions: a correlative study with contrast-enhanced T1-weighted imaging.

Authors:  N Yamada; S Imakita; T Sakuma
Journal:  AJNR Am J Neuroradiol       Date:  1999-02       Impact factor: 3.825

7.  MRI of the pelvis at 3 T: very high spatial resolution with sensitivity encoding and flip-angle sweep technique in clinically acceptable scan time.

Authors:  Nuschin Morakkabati-Spitz; Jürgen Gieseke; Christiane Kuhl; Götz Lutterbey; Marcus von Falkenhausen; Frank Träber; Tjoung-Won Park-Simon; Oliver Zivanovic; Hans H Schild
Journal:  Eur Radiol       Date:  2005-10-14       Impact factor: 5.315

8.  Brain tumors: full- and half-dose contrast-enhanced MR imaging at 3.0 T compared with 1.5 T--Initial Experience.

Authors:  Carsten Krautmacher; Winfried A Willinek; Henriette J Tschampa; Mark Born; Frank Träber; Jürgen Gieseke; Hans J Textor; Hans H Schild; Christiane K Kuhl
Journal:  Radiology       Date:  2005-10-19       Impact factor: 11.105

9.  High-resolution three-dimensional contrast-enhanced blood oxygenation level-dependent magnetic resonance venography of brain tumors at 3 Tesla: first clinical experience and comparison with 1.5 Tesla.

Authors:  Markus Barth; Iris-Melanie Nöbauer-Huhmann; Jürgen R Reichenbach; Vladimir Mlynárik; Andreas Schöggl; Christian Matula; Siegfried Trattnig
Journal:  Invest Radiol       Date:  2003-07       Impact factor: 6.016

Review 10.  MR contrast agent at high-field MRI (3 Tesla).

Authors:  Siegfried Trattnig; Ahmed Ba-Ssalamah; Iris-Melanie Noebauer-Huhmann; Markus Barth; Stefan Wolfsberger; Katja Pinker; Engelbert Knosp
Journal:  Top Magn Reson Imaging       Date:  2003-10
View more
  32 in total

1.  Hyperintense acute reperfusion marker on FLAIR is not associated with early haemorrhagic transformation in the elderly.

Authors:  Michal Rozanski; Martin Ebinger; Wolf U Schmidt; Benjamin Hotter; Sandra Pittl; Peter U Heuschmann; Jan G Jungehuelsing; Jochen B Fiebach
Journal:  Eur Radiol       Date:  2010-07-21       Impact factor: 5.315

2.  Use of normative distribution of gray to white matter ratio in orthogonal planes in human brain studies and computer-assisted neuroradiology.

Authors:  Wieslaw L Nowinski; Varsha Gupta; Wai Yen Chan; Yih-Yian Sitoh; Kang Sim
Journal:  Int J Comput Assist Radiol Surg       Date:  2010-12-16       Impact factor: 2.924

3.  Simple method for whole-brain volumetric T(1)-weighted turbo spin-echo imaging.

Authors:  Masami Yoneyama; Masanobu Nakamura; Makoto Obara; Takashi Namiki; Atsushi Takemura; Satoshi Tatsuno; Seishi Sawano
Journal:  Radiol Phys Technol       Date:  2013-12-04

4.  Contrast enhancement of intracranial lesions at 1.5 T: comparison among 2D spin echo, black-blood (BB) Cube, and BB Cube-FLAIR sequences.

Authors:  SungWoon Im; Ryuichiro Ashikaga; Yukinobu Yagyu; Tetsuya Wakayama; Mitsuharu Miyoshi; Tomoko Hyodo; Izumi Imaoka; Seishi Kumano; Kazunari Ishii; Takamichi Murakami
Journal:  Eur Radiol       Date:  2015-05-01       Impact factor: 5.315

5.  MS lesions are better detected with 3D T1 gradient-echo than with 2D T1 spin-echo gadolinium-enhanced imaging at 3T.

Authors:  A Crombé; M Saranathan; A Ruet; M Durieux; E de Roquefeuil; J C Ouallet; B Brochet; V Dousset; T Tourdias
Journal:  AJNR Am J Neuroradiol       Date:  2014-11-06       Impact factor: 3.825

Review 6.  State-of-the-art MRI techniques in neuroradiology: principles, pitfalls, and clinical applications.

Authors:  Magalie Viallon; Victor Cuvinciuc; Benedicte Delattre; Laura Merlini; Isabelle Barnaure-Nachbar; Seema Toso-Patel; Minerva Becker; Karl-Olof Lovblad; Sven Haller
Journal:  Neuroradiology       Date:  2015-04-10       Impact factor: 2.804

7.  Comparison of lesion enhancement between BB Cube and 3D-SPGR images for brain tumors with 1.5-T magnetic resonance imaging.

Authors:  Hirokazu Hasegawa; Ryuichiro Ashikaga; Kaoru Okajima; Tetsuya Wakayama; Mitsuharu Miyoshi; Yasumasa Nishimura; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2017-05-24       Impact factor: 2.374

8.  Whole-brain black-blood imaging with magnetization-transfer prepared spin echo-like contrast: a novel sequence for contrast-enhanced brain metastasis screening at 3T.

Authors:  Masami Yoneyama; Masanobu Nakamura; Takashi Tabuchi; Atsushi Takemura; Makoto Obara; Satoshi Tatsuno; Seishi Sawano
Journal:  Radiol Phys Technol       Date:  2013-05-05

9.  Usefulness of the Delay Alternating with Nutation for Tailored Excitation Pulse with T1-Weighted Sampling Perfection with Application-Optimized Contrasts Using Different Flip Angle Evolution in the Detection of Cerebral Metastases: Comparison with MPRAGE Imaging.

Authors:  D Kim; Y J Heo; H W Jeong; J W Baek; J-Y Han; J Y Lee; S-C Jin; H J Baek
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

10.  Usefulness of contrast-enhanced T1-weighted sampling perfection with application-optimized contrasts by using different flip angle evolutions in detection of small brain metastasis at 3T MR imaging: comparison with magnetization-prepared rapid acquisition of gradient echo imaging.

Authors:  Y Kato; S Higano; H Tamura; S Mugikura; A Umetsu; T Murata; S Takahashi
Journal:  AJNR Am J Neuroradiol       Date:  2009-02-12       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.